The three-year, multi-country implementation study builds on decades of research related to pre-exposure prophylaxis (PrEP) for HIV prevention and is aimed at assessing the delivery of multiple PrEP methods to women in real-world settings in five African countries, including Zimbabwe. The study will deliver a choice among three PrEP methods — daily pills, a vaginal ring replaced monthly or a long-acting injection given every two months — to an estimated 11,000 participants without HIV across 28 public health service delivery sites supported by the U.S. President’s Emergency Plan for AIDS Research (PEPFAR) in Kenya, Lesotho, South Africa, Uganda and Zimbabwe. Read more on this here